At Blue Latitude Health, Brand Strategy encompasses the development and delivery of customer-focused strategies and plans, which create long-term value to patients and brands.
This is where you’ll find our commentary, articles, and resources that relate to those strategies and plans, and the processes behind them.
| 23rd May 2017
What drives us at BLH is the opportunity to make a real difference – and for our clients, that difference is measured both in customer outcomes and commercial outcomes. In the Executional Excellence edition of Perspective magazine, we explore topics around the ‘executional excellence’ theme – creating work that works.
| 8th May 2017
Turning data into a meaningful and engaging story requires both creative and analytical thinking, and this is the exactly the approach we took in this year’s entry to the 'BHBIA Analyst Team of the Year' competition. Here, Pany Koizi outlines the multi-disciplinary approach used in our journey to the finals of the competition.
| 5th April 2017
Channel strategy has long been a hot topic for pharma and is often regarded as the answer to many of today’s marketing challenges. Head of Brand Strategy Jenna Earl discusses these challenges faced by pharmaceutical marketers today, and if channel disruption is really the answer.
| 29th March 2017
Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.
| 1st March 2017
As companies work to find innovative marketing techniques to cut through the noise, influence mapping has seen an increase in popularity. Associate Consultant Pany Koizi talks through how to get the most out of the influence mapping process.
| 30th September 2016
Creative Director Damien Parsonage breaks down the common misconception that pharma and healthcare marketing for healthcare professionals ought to be entirely scientific and rational. Brands are powerful; here's how to strengthen yours by infusing it with emotion.
| 19th September 2016
Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines.
| 14th September 2016
Senior Account Executive Dave Wood talks us through what DAM and CMS are, the role they play in the future of healthcare marketing, and how they can be best utilised to maximise outcomes for pharma and agencies.
| 8th August 2016
The last few years have seen a huge proliferation in the number of products entering the oncology space, with a lot more currently being investigated in clinical trials. Effective positioning in this situation is vital to cut through the noise, so we've outlined some key learnings from our extensive experience in this area.
| 13th June 2016
In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).